Cancer Family
Salivary Gland Neoplasm
CI-CAN-00000343Explore in graph →
Non-malignant74 active trials13 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000343Explore in graph →
Clinical trials
267 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03146650 | Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer | unknown | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Jan 18, 2024 |
| NCT05898373 | Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC | unknown | Phase 1 / Phase 2 | 120 | Peking Union Medical CollegeOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT04974866 | Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma | unknown | Phase 2 | 20 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05727410 | Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma | unknown | Phase 2 | 50 | Myung-Ju AhnOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05601401 | Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2 | unknown | Phase 2 | 10 | Peking Union Medical College HospitalOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT03614364 | Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma | unknown | Phase 2 | 41 | Samsung Medical CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05008237 | Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study | unknown | Phase 2 | 42 | Samsung Medical CenterOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT02942693 | Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma | unknown | Phase 2 | 50 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02775370 | A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck | unknown | Phase 2 | 68 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Sep 26, 2018 | clinicaltrials |
| NCT02883374 | Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety | unknown | Phase 2 | 30 | Dong meiOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT01192087 | Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy(ACCEPT) | unknown | Phase 1 / Phase 2 | 49 | Heidelberg UniversityOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00180921 | Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck | unknown | Phase 2 | 30 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 26, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Feb 16, 2024source: clinicaltrials